Leuprolide · source year
10 selected, source-linked Leuprolide records carrying a 2023 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
10 selected records.
3 represented types.
10 distinct public records.
Cited chronology
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00541047 at 2026-07-30T19:04:52.204Z. Its registry update date was 2023-11-13, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06106932 at 2026-07-30T19:07:27.301Z. Its registry update date was 2023-10-30, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Safety
FDA's dated enforcement report D-1178-2023 lists Class III and source status Terminated for Tolmar, Inc. PeptideScanner connects the report to reviewed application NDA021379 through exact openFDA application-number annotations.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00002889 at 2026-07-30T19:09:38.368Z. Its registry update date was 2023-08-18, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04897958 at 2026-07-30T19:10:42.712Z. Its registry update date was 2023-07-27, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02058706 at 2026-07-30T19:13:03.747Z. Its registry update date was 2023-05-10, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Regulatory
DailyMed lists Structured Product Labeling version 5 for the reviewed Leuprolide label family with a published date of 2023-03-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00001259 at 2026-07-30T19:15:14.515Z. Its registry update date was 2023-03-02, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Regulatory
The Federal Register published notice 2023-03364, attributed to FDA and its parent HHS department, on 2023-02-17. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Afamelanotide, Glucagon, Leuprolide and Vosoritide.
Source: Federal Register via GovInfo ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03043807 at 2026-07-30T19:16:22.177Z. Its registry update date was 2023-02-16, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗